🚀 VC round data is live in beta, check it out!
Ironwood Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ironwood Pharmaceuticals and similar public comparables like Replimune Group, Boan Biotech, Medy-Tox, Design Therapeutics and more.
Ironwood Pharmaceuticals Overview
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Founded
1998
HQ
Employees
253
Website
Sectors
Financials (LTM)
EV
$1B
Ironwood Pharmaceuticals Financials
Ironwood Pharmaceuticals reported last 12-month revenue of $332M and EBITDA of $174M.
In the same LTM period, Ironwood Pharmaceuticals generated $332M in gross profit, $174M in EBITDA, and $64M in net income.
Revenue (LTM)
Ironwood Pharmaceuticals P&L
In the most recent fiscal year, Ironwood Pharmaceuticals reported revenue of $296M and EBITDA of $138M.
Ironwood Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $332M | XXX | $296M | XXX | XXX | XXX |
| Gross Profit | $332M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | $174M | XXX | $138M | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 47% | XXX | XXX | XXX |
| EBIT Margin | 42% | XXX | 40% | XXX | XXX | XXX |
| Net Profit | $64M | XXX | $24M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | — | — | $369M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ironwood Pharmaceuticals Stock Performance
Ironwood Pharmaceuticals has current market cap of $582M, and enterprise value of $1B.
Market Cap Evolution
Ironwood Pharmaceuticals' stock price is $3.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $582M | 0.0% | XXX | XXX | XXX | $0.15 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIronwood Pharmaceuticals Valuation Multiples
Ironwood Pharmaceuticals trades at 3.1x EV/Revenue multiple, and 6.0x EV/EBITDA.
EV / Revenue (LTM)
Ironwood Pharmaceuticals Financial Valuation Multiples
As of March 21, 2026, Ironwood Pharmaceuticals has market cap of $582M and EV of $1B.
Equity research analysts estimate Ironwood Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ironwood Pharmaceuticals has a P/E ratio of 9.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $582M | XXX | $582M | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 6.0x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBIT | 7.4x | XXX | 8.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.1x | XXX | — | XXX | XXX | XXX |
| P/E | 9.1x | XXX | 24.2x | XXX | XXX | XXX |
| EV/FCF | 6.9x | XXX | 8.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ironwood Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ironwood Pharmaceuticals Margins & Growth Rates
Ironwood Pharmaceuticals' revenue in the last 12 month grew by 40%.
Ironwood Pharmaceuticals' revenue per employee in the last FY averaged $1.3M.
Ironwood Pharmaceuticals' rule of 40 is 92% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ironwood Pharmaceuticals' rule of X is 152% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ironwood Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 40% | XXX | 55% | XXX | XXX | XXX |
| EBITDA Margin | 53% | XXX | 47% | XXX | XXX | XXX |
| EBITDA Growth | 78% | XXX | 122% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 92% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 152% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ironwood Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Replimune Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Boan Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Design Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ironwood Pharmaceuticals M&A Activity
Ironwood Pharmaceuticals acquired XXX companies to date.
Last acquisition by Ironwood Pharmaceuticals was on XXXXXXXX, XXXXX. Ironwood Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ironwood Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialIronwood Pharmaceuticals Investment Activity
Ironwood Pharmaceuticals invested in XXX companies to date.
Ironwood Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Ironwood Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ironwood Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ironwood Pharmaceuticals
| When was Ironwood Pharmaceuticals founded? | Ironwood Pharmaceuticals was founded in 1998. |
| Where is Ironwood Pharmaceuticals headquartered? | Ironwood Pharmaceuticals is headquartered in United States. |
| How many employees does Ironwood Pharmaceuticals have? | As of today, Ironwood Pharmaceuticals has over 253 employees. |
| Who is the CEO of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals' CEO is Thomas A. McCourt. |
| Is Ironwood Pharmaceuticals publicly listed? | Yes, Ironwood Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals trades under IRWD ticker. |
| When did Ironwood Pharmaceuticals go public? | Ironwood Pharmaceuticals went public in 2010. |
| Who are competitors of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals main competitors are Replimune Group, Boan Biotech, Medy-Tox, Design Therapeutics. |
| What is the current market cap of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals' current market cap is $582M. |
| What is the current revenue of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals' last 12 months revenue is $332M. |
| What is the current revenue growth of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals revenue growth (NTM/LTM) is 40%. |
| What is the current EV/Revenue multiple of Ironwood Pharmaceuticals? | Current revenue multiple of Ironwood Pharmaceuticals is 3.1x. |
| Is Ironwood Pharmaceuticals profitable? | Yes, Ironwood Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals' last 12 months EBITDA is $174M. |
| What is Ironwood Pharmaceuticals' EBITDA margin? | Ironwood Pharmaceuticals' last 12 months EBITDA margin is 53%. |
| What is the current EV/EBITDA multiple of Ironwood Pharmaceuticals? | Current EBITDA multiple of Ironwood Pharmaceuticals is 6.0x. |
| What is the current FCF of Ironwood Pharmaceuticals? | Ironwood Pharmaceuticals' last 12 months FCF is $151M. |
| What is Ironwood Pharmaceuticals' FCF margin? | Ironwood Pharmaceuticals' last 12 months FCF margin is 45%. |
| What is the current EV/FCF multiple of Ironwood Pharmaceuticals? | Current FCF multiple of Ironwood Pharmaceuticals is 6.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.